Springer Seminars in Immunopathology

, Volume 23, Issue 1, pp 193–213

Stem cell transplantation for autoimmune diseases

Futurology

DOI: 10.1007/s002810100059

Cite this article as:
Moore, J. & Brooks, P. Springer Semin Immunopathol (2001) 23: 193. doi:10.1007/s002810100059
  • 35 Downloads

Conclusion

HSCT in autoimmune diseases has now become one of the potential therapeutic options for physicians looking after patients with severe intractable autoimmune diseases. It has now progressed beyond theory based on animal and human case reports, but at this stage it has been appropriately reserved for patients with resistant disease in a clinical trial setting. Ongoing analysis of the safety and efficacy of patients in phase I/II trials will allow us to determine if there is a wider role for the procedure in diseases such as RA, SLE, SSc and MS. Meta-analyses of the data will enable appropriate selection of patients and the optimal transplant procedure, so that eventually randomised trials against gold standard therapy will become a reality. In the future, with a decreased morbidity and mortality from allogeneic transplantation, cure of these diseases is not an unrealistic option.

Copyright information

© Springer-Verlag 2001

Authors and Affiliations

  1. 1.Faculty of Health SciencesUniversity of QueenslandBrisbaneAustralia
  2. 2.Haematology DepartmentSt. Vincents HospitalAustralia